AU3408097A - Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists - Google Patents

Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists

Info

Publication number
AU3408097A
AU3408097A AU34080/97A AU3408097A AU3408097A AU 3408097 A AU3408097 A AU 3408097A AU 34080/97 A AU34080/97 A AU 34080/97A AU 3408097 A AU3408097 A AU 3408097A AU 3408097 A AU3408097 A AU 3408097A
Authority
AU
Australia
Prior art keywords
seroto
nin
dopamine
agonists
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU34080/97A
Inventor
Anthony H Cincotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ergo Research Corp
Original Assignee
Ergo Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ergo Research Corp filed Critical Ergo Research Corp
Publication of AU3408097A publication Critical patent/AU3408097A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU34080/97A 1996-06-06 1997-06-06 Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists Abandoned AU3408097A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1920996P 1996-06-06 1996-06-06
US60019209 1996-06-06
PCT/US1997/010838 WO1997046239A1 (en) 1996-06-06 1997-06-06 Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists

Publications (1)

Publication Number Publication Date
AU3408097A true AU3408097A (en) 1998-01-05

Family

ID=21792005

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34080/97A Abandoned AU3408097A (en) 1996-06-06 1997-06-06 Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists

Country Status (4)

Country Link
JP (1) JP2000513337A (en)
AU (1) AU3408097A (en)
CA (1) CA2257084A1 (en)
WO (1) WO1997046239A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262049B1 (en) 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
IL135659A0 (en) * 1997-10-28 2001-05-20 Schering Corp Method of reducing craving in mammals
NO328803B1 (en) * 2000-03-03 2010-05-18 Thia Medica New fatty acid analogues
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2008014299A2 (en) * 2006-07-27 2008-01-31 Allergan, Inc. Use of an alpha2-agonist composition for the treatment of hyperlipidemia
US8604035B2 (en) 2011-06-23 2013-12-10 Map Pharmaceuticals, Inc. Fluoroergoline analogs
SG11201403434YA (en) * 2011-12-19 2014-09-26 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
EP2793583A4 (en) 2011-12-21 2015-08-12 Map Pharmaceuticals Inc Novel neuromodulatory compounds
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
EP3253753A4 (en) 2015-01-20 2018-06-27 Xoc Pharmaceuticals, Inc Ergoline compounds and uses thereof
US9676776B2 (en) 2015-01-20 2017-06-13 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
AU2018275873A1 (en) 2017-06-01 2019-12-19 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783469A (en) * 1986-03-07 1988-11-08 Meier Albert H Method of inhibiting body fat stores
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
EP0370560B1 (en) * 1988-11-24 1994-01-12 Akzo Nobel N.V. Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines

Also Published As

Publication number Publication date
JP2000513337A (en) 2000-10-10
CA2257084A1 (en) 1997-12-11
WO1997046239A1 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
AU4986899A (en) Non-invasive glucose monitor
AU3106797A (en) Lipid metabolism improving agent
AU3473597A (en) Non-invasive glucose measuring device and method for measuring blood glucose
AU5694199A (en) Intravascular cannulation apparatus and methods of use
AU6604898A (en) Catheters and endoscopes comprising optical probes and bioptomes and methods of using the same
IL213041A0 (en) Use of hypoglycemic agent for treating impaired glucose metabolism
AU3408097A (en) Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists
AU7107394A (en) Noninvasive glucose monitor
AU2710500A (en) Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
AU4078997A (en) Cholinesterase inhibitors for treatment of parkinson's disease
EP0968719A3 (en) Enzyme composition capable of forming an oligosaccharide in vivo
AU3876499A (en) Non-invasive measurement of blood glucose
AU4224600A (en) Composition and method for treatment of inflammation and pain in mammals
AU7358800A (en) Compositions and methods for modification of skin lipid content
ZA9711159B (en) Immobilized enzyme and its use for the processing of triglyceride oils
AU5101599A (en) Tetrahydrofolate metabolism enzymes
AU6163999A (en) Holographic desktop monitor
AU2454701A (en) Advanced alloy fiber and process of making
AU3616397A (en) Transparent ball with insert, and process of manufacture thereof
AU4031500A (en) Edible solids for treatment of glucose metabolism disorders
AU1476901A (en) Methods for regulating blood glucose and appetite suppression in type 2 diabetics
AU4326500A (en) Beverages for treatment of glucose metabolism disorders
EP1135119A4 (en) Glucose and lipid lowering compounds
AU7378400A (en) Peroxisome proliferator-activated receptor alpha and disorders of lipid metabolism
AU1700897A (en) Methods and apparatus for non-invasive glucose sensing: spectrograph